Bristol Myers Squibb’s Breyanzi Shows Promising Results in Three Lymphoma Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has announced results from three distinct clinical trials assessing...
Drug
AbelZeta and AstraZeneca’s C-CAR031 Shows Promising Results in HCC Treatment
AbelZeta, a Sino-US biotech company with operations in Rockville, Maryland, and Shanghai, has presented data...
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428),...
Jiangsu Hengrui Receives NMPA Approval to Begin Clinical Trials for New Anticancer Biologic
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
AIM Vaccine Submits Pre-IND Applications for mRNA Vaccines Targeting RSV and Herpes Zoster to NMPA
AIM Vaccine Co., Ltd (HKG: 6660), a biopharmaceutical company based in China, has announced the...
Olymvax Bio Receives Ethical Approval for Oral Helicobacter pylori Vaccine Trial in Australia
Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced...
Sanofi Receives NMPA Approval for Phase III Clinical Trial of RSV Vaccine SP0125
Sanofi (EPA: SAN), a major French multinational pharmaceutical company, has announced that it has received...
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA
Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...
Gilead and Arcus Biosciences Report Positive Combination Therapy Results in mCRC Trial
Biopharmaceutical companies Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced safety and efficacy...
AstraZeneca’s Tagrisso Achieves Milestone Progression-Free Survival in Late-Stage Lung Cancer Study
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has announced preliminary results from...
MicuRx Pharmaceuticals’ MRX-8 Achieves Positive Results in Phase I Clinical Study
MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has announced the successful completion...
Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Recommended for Approval by EMA’s CHMP
Bio-Thera Solutions (SHA: 688177), a biopharmaceutical company based in Guangzhou, has received notification that the...
Akeso Expands Licensing Deal with Summit Therapeutics for Ivonescimab Bispecific Antibody
Akeso Inc. (HKG: 9926), a biopharmaceutical company based in China, has announced a supplementary licensing...
Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...
Legend Biotech’s Carvykti Shows Durable Responses in Multiple Myeloma Patients Post ASCT
Legend Biotech Corporation (NASDAQ: LEGN) has announced results from the Phase II CARTITUDE-2 Cohort D...
CSPC Pharmaceutical Secures NMPA Nod for Generic Version of AstraZeneca’s Lynparza
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Akeso Biopharma’s Ivonescimab Outshines Keytruda in NSCLC Trial, Raises FDA Concerns
FiercePharma.com has reported on the reactions of multinational corporation executives to the recent news that...
Gilead and Arcus Biosciences Report Positive Interim Phase II Data for Domvanalimab Combo in GI Cancers
Gilead (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have announced interim Phase II data for...
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...